IDEXX Laboratories's EBIT per Share for the
three
months ended in Mar. 2026 was €3.92.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €15.03.
During the past 12 months, the average EBIT per Share Growth Rate of IDEXX Laboratories was 25.90% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 16.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 14.00% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 17.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for IDEXX Laboratories's EBIT per Share or its related term are showing as below:
FRA:IX1'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -6.2 Med: 17.6 Max: 73
Current: 16.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of IDEXX Laboratories was 73.00% per year. The lowest was -6.20% per year. And the median was 17.60% per year.
FRA:IX1's 3-Year EBIT Growth Rate is ranked better than 55.95% of 168
companies
in the Medical Diagnostics & Research industry
Industry Median: 12.75
vs FRA:IX1: 16.50
IDEXX Laboratories (FRA:IX1) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
IDEXX Laboratories EBIT per Share Related Terms
IDEXX Laboratories EBIT per Share Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €15.03
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDEXX Laboratories (FRA:IX1) has a EBIT per Share of €15.03 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on IDEXX Laboratories and its competitors. According to the industry distribution chart, IDEXX Laboratories ranks #74 out of 168 companies in the Medical Diagnostics & Research industry, placing it in the top 44%.
Is IDEXX Laboratories' EBIT per Share too high?
IDEXX Laboratories' current EBIT per Share is €15.03. Based on the distribution chart, IDEXX Laboratories ranks #74 out of 168 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' EBIT per Share compare to A and NTRA?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #74 out of 168 companies for EBIT per Share. This puts IDEXX Laboratories in the upper half of its industry. The industry median EBIT per Share is 12.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Diagnostics & Research company?
The median EBIT per Share among Medical Diagnostics & Research companies is 12.75, based on 168 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on IDEXX Laboratories and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEXX Laboratories's current EBIT per Share is €15.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €551.02, compared to a current price of €486.30 — trading 11.7% below its estimated fair value. The current EBIT per Share is €15.03. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current EBIT per Share is €15.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €486.30 is trading 11.7% below its estimated GF Value™ of €551.02.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:IX1:
EBIT per Share: €15.03
GF Value™: €551.02 vs. price of €486.30 (11.7% below fair value)
No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for FRA:IX1
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IX1 has been successfully added to your 
